Diligence memo · auto-generated · as of July 2, 2026
AeroRx Therapeutics, Inc.
AeroRx Therapeutics, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
AeroRx Therapeutics, Inc. operates in Pharma, based in LA JOLLA.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
AeroRx Therapeutics, Inc. has raised $10M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $10M on 2025-09-25.
Most recent recorded round closed around 2025-09-25.
Valuation (modeled)modeled
Provath models AeroRx Therapeutics, Inc. at approximately $31M (range $12M–$50M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.00× the median modeled value of Series A Pharma companies in 2025–2027 (9 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 9 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 66% of Pharma peers (310 compared).
Modeled value ranks above 49% of those peers.
Closest niche peers: Neela Therapeutics, Inc., Cirrus Therapeutics, Inc., Kamau Therapeutics, Inc., Merge Bio Therapeutics Corp, PanTher Therapeutics, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.